Novartis commits US$ 250 million to the fight against NTDs and malaria
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Subscribe To Our Newsletter & Stay Updated